Advertisement

Mitoxantrone, Cytosine Arabinoside, and VP-16 in 36 Patients with Relapsed and Refractory Acute Myeloid Leukemia

  • H. Link
  • M. Freund
  • H. Diedrich
  • H. Wilke
  • J. Austein
  • M. Henke
  • H. Wandt
  • E. Fackler-Schwalbe
  • G. Schlimok
  • R. Hoffmann
  • A. Calavrezos
  • H. Poliwoda
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 33)

Abstract

With intensive induction therapy, complete remission can be achieved in 60%-80% of previously untreated adult patients with acute myeloid leukemia (AML) when a combination of cytarabine arabinoside (Ara-C) and daunorubicin is used [1]. However, half of these patients relapse within 12–16 months. Effective cytostatic drugs and combination therapy schemes need to be developed for those patients whose leukemia cells are primary refractory to Ara-C and daunorubicin or become resistant in relapse.

Keywords

Acute Myeloid Leukemia Complete Remission Induction Therapy Acute Leukemia Cytosine Arabinoside 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Champlin RE, Gale RP (1987) Acute myelogenous leukemia: recent advances in therapy. Blood 69: 1551–1562PubMedGoogle Scholar
  2. 2.
    Ho AD, Lipp T, Ehninger G, Iiiiger HJ, Meyer P, Freund M, Hunstein W (1988) Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia — an active and well-tolerated regimen. J Clin Oncol 6: 213–217PubMedGoogle Scholar
  3. 3.
    Meyer P, Ho AD, Ehninger G, Mjaaland I, Heidemann E, Seither E (1985) Mitoxantrone in the treatment of relapsed and refractory acute leukemia. Invest New Drugs 3: 203–206PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • H. Link
    • 1
  • M. Freund
    • 1
  • H. Diedrich
    • 1
  • H. Wilke
    • 1
  • J. Austein
    • 1
  • M. Henke
    • 2
  • H. Wandt
    • 3
  • E. Fackler-Schwalbe
    • 4
  • G. Schlimok
    • 4
  • R. Hoffmann
    • 5
  • A. Calavrezos
    • 5
  • H. Poliwoda
    • 1
  1. 1.Dept. of Hematology-OncologyMedical SchoolHannoverGermany
  2. 2.Dept. of Internal MedicineUniversity of FreiburgGermany
  3. 3.Dept. of Internal MedicineNürnbergGermany
  4. 4.Dept. of Internal MedicineAugsburgGermany
  5. 5.Dept. of HematologyKrankenhaus St. GeorgGermany

Personalised recommendations